상세 보기
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
- Kim, KyeongJin;
- Yang, Wen-Hao;
- Jung, Youn-Sang;
- Cha, Jong-Ho
WEB OF SCIENCE
29SCOPUS
27초록
T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-T-cells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend's potential as an adjuvant for cancer immunotherapy.
키워드
- 제목
- A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
- 저자
- Kim, KyeongJin; Yang, Wen-Hao; Jung, Youn-Sang; Cha, Jong-Ho
- 발행일
- 2020-10-31
- 유형
- Review
- 저널명
- BMB Reports
- 권
- 53
- 호
- 10
- 페이지
- 512 ~ 520